• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neumora Therapeutics, Inc. - Common Stock (NQ: NMRA )

    10.78 -0.54 (-4.73%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Neumora Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 12, 2024
    Via Benzinga
    Neumora Therapeutics to Participate in Upcoming Conferences in November
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga
    Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
    Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET 
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
    NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
    NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    Neumora Therapeutics to Participate in Upcoming Conferences in May
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
    U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Crude Oil Down 1%; Charles Schwab Sales Top Estimates
    U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
    Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution. 
    Via Benzinga
    Exposures Product Safety
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
    Via Benzinga
    Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
    The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
    Via Investor's Business Daily
    Why Is Mobile Global Esports (MGAM) Stock Down 18% Today?
    Mobile Global Esports stock is falling on Monday after the company revealed that shares of MGAM will be delisted later this week. 
    Via InvestorPlace
    Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
    Neumora Therapeutics stock is falling on Monday as investors in NMRA shares react to a clinical trial being put on hold by the FDA. 
    Via InvestorPlace
    Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
    Via InvestorPlace
    Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
    U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
    Via Benzinga
    NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023
    NMRA stock results show that Neumora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.